Does the media favor VRTX or ALNY?

In the previous week, Vertex Pharmaceuticals had 19 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 37 mentions for Vertex Pharmaceuticals and 18 mentions for Alnylam Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.06 beat Alnylam Pharmaceuticals' score of 0.82 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vertex Pharmaceuticals 25 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 11 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BIIB or ALNY?

In the previous week, Biogen had 8 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 26 mentions for Biogen and 18 mentions for Alnylam Pharmaceuticals. Biogen's average media sentiment score of 0.90 beat Alnylam Pharmaceuticals' score of 0.82 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 14 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 11 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor UTHR or ALNY?

In the previous week, United Therapeutics had 1 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 19 mentions for United Therapeutics and 18 mentions for Alnylam Pharmaceuticals. United Therapeutics' average media sentiment score of 0.85 beat Alnylam Pharmaceuticals' score of 0.82 indicating that United Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 13 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 11 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to INCY or ALNY?

In the previous week, Alnylam Pharmaceuticals had 7 more articles in the media than Incyte. MarketBeat recorded 18 mentions for Alnylam Pharmaceuticals and 11 mentions for Incyte. Incyte's average media sentiment score of 1.01 beat Alnylam Pharmaceuticals' score of 0.82 indicating that Incyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 11 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Alnylam Pharmaceuticals (ALNY) Competitors

$288.18 +1.77 (+0.62%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$286.75 -1.43 (-0.50%)

As of 04:00 AM Eastern

Compare

ALNY vs. VRTX, REGN, BIIB, UTHR, and INCY

Should you buy Alnylam Pharmaceuticals stock or one of its competitors? MarketBeat compares Alnylam Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alnylam Pharmaceuticals include Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), United Therapeutics (UTHR), and Incyte (INCY). These companies are all part of the "biotechnology" industry.

How does Alnylam Pharmaceuticals compare to Vertex Pharmaceuticals?

Vertex Pharmaceuticals (NASDAQ:VRTX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

Vertex Pharmaceuticals has a net margin of 35.51% compared to Alnylam Pharmaceuticals' net margin of 11.72%. Alnylam Pharmaceuticals' return on equity of 85.76% beat Vertex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vertex Pharmaceuticals	35.51%	23.86%	17.13%
Alnylam Pharmaceuticals	11.72%	85.76%	10.32%

91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 0.2% of Vertex Pharmaceuticals shares are owned by insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Vertex Pharmaceuticals has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market.

Vertex Pharmaceuticals currently has a consensus target price of $555.91, indicating a potential upside of 18.68%. Alnylam Pharmaceuticals has a consensus target price of $463.13, indicating a potential upside of 60.71%. Given Alnylam Pharmaceuticals' higher probable upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Vertex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vertex Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.88
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.85

Vertex Pharmaceuticals has higher revenue and earnings than Alnylam Pharmaceuticals. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vertex Pharmaceuticals	$12.22B	9.73	$3.95B	$16.86	27.78
Alnylam Pharmaceuticals	$3.71B	10.36	$313.75M	$3.66	78.74

In the previous week, Vertex Pharmaceuticals had 19 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 37 mentions for Vertex Pharmaceuticals and 18 mentions for Alnylam Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.06 beat Alnylam Pharmaceuticals' score of 0.82 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vertex Pharmaceuticals	25 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	11 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vertex Pharmaceuticals beats Alnylam Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Alnylam Pharmaceuticals compare to Regeneron Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

Regeneron Pharmaceuticals has higher revenue and earnings than Alnylam Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	10.36	$313.75M	$3.66	78.74
Regeneron Pharmaceuticals	$14.34B	4.56	$4.50B	$41.04	15.06

Alnylam Pharmaceuticals has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market.

In the previous week, Regeneron Pharmaceuticals had 11 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 29 mentions for Regeneron Pharmaceuticals and 18 mentions for Alnylam Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 1.48 beat Alnylam Pharmaceuticals' score of 0.82 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	11 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Regeneron Pharmaceuticals	25 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Alnylam Pharmaceuticals currently has a consensus target price of $463.13, indicating a potential upside of 60.71%. Regeneron Pharmaceuticals has a consensus target price of $792.65, indicating a potential upside of 28.25%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.85
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.70

Regeneron Pharmaceuticals has a net margin of 29.65% compared to Alnylam Pharmaceuticals' net margin of 11.72%. Alnylam Pharmaceuticals' return on equity of 85.76% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	11.72%	85.76%	10.32%
Regeneron Pharmaceuticals	29.65%	13.16%	10.17%

Summary

Alnylam Pharmaceuticals beats Regeneron Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Alnylam Pharmaceuticals compare to Biogen?

Biogen (NASDAQ:BIIB) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Biogen has a net margin of 13.81% compared to Alnylam Pharmaceuticals' net margin of 11.72%. Alnylam Pharmaceuticals' return on equity of 85.76% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	13.81%	12.83%	8.01%
Alnylam Pharmaceuticals	11.72%	85.76%	10.32%

Biogen currently has a consensus target price of $217.37, indicating a potential upside of 10.23%. Alnylam Pharmaceuticals has a consensus target price of $463.13, indicating a potential upside of 60.71%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	12 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.57
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.85

87.9% of Biogen shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 0.3% of Biogen shares are owned by insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Biogen has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.29, indicating that its stock price is 71% less volatile than the broader market.

Biogen has higher revenue and earnings than Alnylam Pharmaceuticals. Biogen is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	2.94	$1.29B	$9.32	21.16
Alnylam Pharmaceuticals	$3.71B	10.36	$313.75M	$3.66	78.74

In the previous week, Biogen had 8 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 26 mentions for Biogen and 18 mentions for Alnylam Pharmaceuticals. Biogen's average media sentiment score of 0.90 beat Alnylam Pharmaceuticals' score of 0.82 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	14 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	11 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Alnylam Pharmaceuticals beats Biogen on 11 of the 17 factors compared between the two stocks.

How does Alnylam Pharmaceuticals compare to United Therapeutics?

United Therapeutics (NASDAQ:UTHR) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

United Therapeutics currently has a consensus target price of $619.42, suggesting a potential upside of 13.79%. Alnylam Pharmaceuticals has a consensus target price of $463.13, suggesting a potential upside of 60.71%. Given Alnylam Pharmaceuticals' higher probable upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.85

United Therapeutics has a net margin of 40.62% compared to Alnylam Pharmaceuticals' net margin of 11.72%. Alnylam Pharmaceuticals' return on equity of 85.76% beat United Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	40.62%	19.24%	17.25%
Alnylam Pharmaceuticals	11.72%	85.76%	10.32%

94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 8.6% of United Therapeutics shares are owned by insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

United Therapeutics has higher earnings, but lower revenue than Alnylam Pharmaceuticals. United Therapeutics is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	7.26	$1.33B	$27.09	20.09
Alnylam Pharmaceuticals	$3.71B	10.36	$313.75M	$3.66	78.74

United Therapeutics has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market.

In the previous week, United Therapeutics had 1 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 19 mentions for United Therapeutics and 18 mentions for Alnylam Pharmaceuticals. United Therapeutics' average media sentiment score of 0.85 beat Alnylam Pharmaceuticals' score of 0.82 indicating that United Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	13 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	11 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

United Therapeutics beats Alnylam Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Alnylam Pharmaceuticals compare to Incyte?

Incyte (NASDAQ:INCY) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

97.0% of Incyte shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 16.2% of Incyte shares are owned by insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Alnylam Pharmaceuticals had 7 more articles in the media than Incyte. MarketBeat recorded 18 mentions for Alnylam Pharmaceuticals and 11 mentions for Incyte. Incyte's average media sentiment score of 1.01 beat Alnylam Pharmaceuticals' score of 0.82 indicating that Incyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	11 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Incyte has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market.

Incyte presently has a consensus target price of $106.90, suggesting a potential upside of 2.39%. Alnylam Pharmaceuticals has a consensus target price of $463.13, suggesting a potential upside of 60.71%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	0 Sell rating(s)	14 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.36
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.85

Incyte has a net margin of 26.71% compared to Alnylam Pharmaceuticals' net margin of 11.72%. Alnylam Pharmaceuticals' return on equity of 85.76% beat Incyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	26.71%	26.66%	19.77%
Alnylam Pharmaceuticals	11.72%	85.76%	10.32%

Incyte has higher revenue and earnings than Alnylam Pharmaceuticals. Incyte is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	4.06	$1.29B	$7.08	14.75
Alnylam Pharmaceuticals	$3.71B	10.36	$313.75M	$3.66	78.74

Summary

Incyte beats Alnylam Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get Alnylam Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALNY vs. The Competition

Export

Metric	Alnylam Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$38.24B	$3.45B	$6.44B	$12.38B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	78.74	19.75	24.67	23.99
Price / Sales	10.36	330.65	528.41	106.93
Price / Cash	102.43	128.56	44.82	54.51
Price / Book	48.27	8.29	10.76	6.50
Net Income	$313.75M	$23.85M	$3.56B	$336.88M
7 Day Performance	1.93%	2.87%	1.03%	-0.14%
1 Month Performance	-3.12%	2.19%	0.45%	0.77%
1 Year Performance	-11.33%	55.48%	29.69%	28.49%

Alnylam Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALNY Alnylam Pharmaceuticals	4.4014 of 5 stars	$288.18 +0.6%	$463.13 +60.7%	-8.0%	$38.24B	$3.71B	78.74	2,770	Analyst Downgrade
VRTX Vertex Pharmaceuticals	4.2887 of 5 stars	$450.46 +1.2%	$555.91 +23.4%	+5.6%	$112.92B	$12.00B	26.72	6,400	Positive News Insider Trade
REGN Regeneron Pharmaceuticals	4.888 of 5 stars	$614.98 +0.5%	$792.65 +28.9%	+20.7%	$64.72B	$14.34B	14.98	15,410	Positive News
BIIB Biogen	3.8978 of 5 stars	$198.64 -0.7%	$216.70 +9.1%	+58.1%	$29.53B	$9.89B	21.31	7,500	Analyst Forecast
UTHR United Therapeutics	4.3555 of 5 stars	$549.57 +0.7%	$619.42 +12.7%	+90.1%	$23.17B	$3.18B	20.29	1,400	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALNY) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alnylam Pharmaceuticals (ALNY) Competitors

ALNY vs. VRTX, REGN, BIIB, UTHR, and INCY

How does Alnylam Pharmaceuticals compare to Vertex Pharmaceuticals?

Summary

How does Alnylam Pharmaceuticals compare to Regeneron Pharmaceuticals?

Summary

How does Alnylam Pharmaceuticals compare to Biogen?

Summary

How does Alnylam Pharmaceuticals compare to United Therapeutics?

Summary

How does Alnylam Pharmaceuticals compare to Incyte?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALNY vs. The Competition

Alnylam Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alnylam Pharmaceuticals (ALNY) Competitors

ALNY vs. VRTX, REGN, BIIB, UTHR, and INCY

How does Alnylam Pharmaceuticals compare to Vertex Pharmaceuticals?

Is VRTX or ALNY more profitable?

Do institutionals and insiders hold more shares of VRTX or ALNY?

Which has more risk & volatility, VRTX or ALNY?

Do analysts prefer VRTX or ALNY?

Which has preferable valuation & earnings, VRTX or ALNY?

Does the media favor VRTX or ALNY?

Summary

How does Alnylam Pharmaceuticals compare to Regeneron Pharmaceuticals?

Which has better valuation & earnings, ALNY or REGN?

Which has more risk and volatility, ALNY or REGN?

Does the media prefer ALNY or REGN?

Do insiders and institutionals have more ownership in ALNY or REGN?

Do analysts prefer ALNY or REGN?

Is ALNY or REGN more profitable?

Summary

How does Alnylam Pharmaceuticals compare to Biogen?

Is BIIB or ALNY more profitable?

Do analysts recommend BIIB or ALNY?

Do institutionals and insiders have more ownership in BIIB or ALNY?

Which has more volatility and risk, BIIB or ALNY?

Which has stronger valuation & earnings, BIIB or ALNY?

Does the media refer more to BIIB or ALNY?

Summary

How does Alnylam Pharmaceuticals compare to United Therapeutics?

Do analysts prefer UTHR or ALNY?

Is UTHR or ALNY more profitable?

Do insiders & institutionals hold more shares of UTHR or ALNY?

Which has better valuation and earnings, UTHR or ALNY?

Which has more volatility and risk, UTHR or ALNY?

Does the media favor UTHR or ALNY?

Summary

How does Alnylam Pharmaceuticals compare to Incyte?

Do institutionals & insiders believe in INCY or ALNY?

Does the media refer more to INCY or ALNY?

Which has more risk and volatility, INCY or ALNY?

Do analysts rate INCY or ALNY?

Is INCY or ALNY more profitable?

Which has preferable valuation & earnings, INCY or ALNY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALNY vs. The Competition

Alnylam Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools